AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02324023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Description: All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
Study NCT01388530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS 7500 Digital Muscle Stimulator
Description: A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
Study NCT03537053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A plan to Move a Little and Often
Description: The intervention content is reported using the behaviour change technique (BCT) Taxonomy v1 (Michie, et al. 2013). The video will contain the BCT: information about health consequences. The booklet will consist of BCTs: self-monitoring of behaviour, goal setting behaviour, action planning, commitment, social support (practical), self-talk, and mental rehearsal of successful performance. Lastly, usage of the Facebook group will include BCTs: commitment, and social support unspecified, practical and emotional.~Mental rehearsal, goal setting behaviour and action planning will be delivered through mental simulation exercises (Taylor, et al. 1998). BCTs self-monitoring of behaviour, goal setting behaviour, and commitment will be delivered using implementation intentions (Gollwitzer 1993).
Study NCT01613092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incremental
Description: Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
Study NCT01613092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Preoperative antibiotic
Study NCT01774916 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples
Study NCT00548912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Spironolactone
Study NCT03069638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
Study NCT03069638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
Study NCT03069638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives/Hypnotics,Other
Description: Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
Study NCT03069638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedatives/Hypnotics,Other
Description: Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
Study NCT02719054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting
Description: A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum.
Study NCT01161836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Solution for infusion~60-minute intravenous infusion
Study NCT04020874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HuTT-2x
Description: tackling and blocking training twice/week
Study NCT04020874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HuTT-4x
Description: tackling and blocking training four times/week
Study NCT00852930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser and MLD combined
Description: The intervention is therapist administered laser and mld treatment combined
Study NCT00852930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser alone
Description: The intervention is therapist administered laser
Study NCT00852930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual lymphatic drainage
Description: The intervention is therapist administered manual lymphatic drainage
Study NCT01368068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone
Description: 2.5mg/oral/daily
Study NCT01368068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10mg/oral/daily
Study NCT01368068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natvia
Description: serving size: 0.09g per tablet
Study NCT02183389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT02183389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT02183389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study NCT01565525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal focused intervention
Description: This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
Study NCT03289000 — intervention group
Intervention type: DEVICE
Intervention: iTotal Posterior Stabilized (PS) Knee Replacement System
Description: Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
Study NCT00593073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic tailored messaging
Description: Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
Study NCT00593073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Reminder Message
Description: General CRC health education message and reminder to get screened.
Study NCT03698019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04180449 — intervention group
Intervention type: OTHER
Intervention: Screening for dysphagia along clinical routine
Description: Screening for dysphagia using the water swallow test in intermediate care unit patients
Study NCT01565525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ounce of Prevention
Description: This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
Study NCT03982225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene phosphatidylcholine injection
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
Study NCT03982225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study NCT02087553 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infusion of albumin/saline
Description: (non-experimental) albumin/saline infusion
Study NCT00583453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery
Study NCT02111811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Veterans Work and Health Initiative
Description: CBT based intervention focused on work productivity
Study NCT01923610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-\~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16
Study NCT01458769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10276
Description: C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
Study NCT01458769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10276
Description: C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
Study NCT01458769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10297
Description: C-10297 200 mg, oral, single dose
Study NCT01458769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10299
Description: C-10299 200 mg, oral, single dose
Study NCT01458769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10297
Description: C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
Study NCT01458769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10299
Description: C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
Study NCT01458769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10276
Description: C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
Study NCT01458769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reyataz®
Description: Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
Study NCT02851446 — intervention group
Intervention type: OTHER
Intervention: measure dyspnoea> Borg 7
Study NCT02270177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine, videoconsultation
Description: We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
Study NCT02957773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong and art activities
Description: Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
Study NCT02957773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art activities
Description: Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
Study NCT02957773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
Study NCT00583453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery
Study NCT03657550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levamlodipine, Amlodipine
Description: In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
Study NCT03657550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine, Levamlodipine
Description: In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
Study NCT00893685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless monitors for disease specific clinical parameters.
Description: Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
Study NCT00455312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: 10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
Study NCT00455312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
Study NCT00455312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
Study NCT00455312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 1 day before the transplant one dose (200 cGy) of total body irradiation is given
Study NCT00455312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.
Study NCT00455312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin
Description: ATG (rabbit) 3 mg/kg for 3 days.
Study NCT00455312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
Study NCT00886522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone cord blood infusion
Description: Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27
Study NCT02903407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
Study NCT02903407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
Study NCT02903407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
Study NCT00627016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: 30 mg capsule, orally, once daily for 4 weeks
Study NCT03097536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luna Bar
Description: Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
Study NCT00747058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3864086
Description: The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
Study NCT02957773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily activities
Description: Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
Study NCT05674773 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic or surgical resection
Description: endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
Study NCT00627016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule, orally, once daily for 4 weeks
Study NCT00910052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tisseelä fibrin sealant
Description: Fibrin sealant applied intraoperatively
Study NCT03792958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082
Description: CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
Study NCT02179398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allocation to the Lab-score group
Study NCT02179398 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allocation to the control group
Study NCT03928873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low energy ESWT
Description: 1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks
Study NCT03928873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High energy ESWT
Description: 1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks
Study NCT03928873 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ESWT
Description: sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
Study NCT03803215 — intervention group
Intervention type: DRUG
Intervention: Theophylline
Description: Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
Study NCT03844438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480226
Description: The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
Study NCT04837391 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy (NIRS)
Description: Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
Study NCT04837391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
Study NCT04837391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Addenbrooke Cognitive Examination III (ACE-III)
Description: ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
Study NCT04837391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confusion Assessment Method
Description: Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
Study NCT04169477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFAR Primo Pro (TENS device)
Description: During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~\[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer.
Study NCT02615301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailor-made salmon with high levels of vitamin D3 and K1
Description: The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
Study NCT02615301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailor-made salmon with low levels of vitamin D3 and high K1
Description: The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
Study NCT02514382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC or IV
Study NCT02514382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO, IV, or IM
Study NCT02514382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00747058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01467258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Single dose
Study NCT00614198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten- and casein-free diet
Description: Removal of foods containing gluten (cereal produce) and casein (dairy produce)
Study NCT02514382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies